Development of Hormonal Intravaginal Rings: Technology and Challenges
Authors:
Open Access
- 13 July 2021
- journal article
- review article
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 81 (07) , 789-806
Abstract
Intravaginal rings (IVRs) are minimally invasive polymeric devices specifically designed to be used for the sustained and prolonged release of various type of drugs such as hormones. One of the benefits of using topical drug delivery systems (e.g., IVRs) is the fact that systemic drug delivery may cause drug resistance due to elevated drug levels. Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects. In addition, when a drug is administered vaginally, the hepatic first-pass effect is avoided, resulting in higher absorption. Contraception and treatments for specific diseases such as endometriosis and hormone deficiencies can be improved by the administration of hormones via an IVR. This article aims to classify and compare various designs of commercially available and non-commercial hormonal IVRs and to analyze their performance. Current challenges affecting the development of IVRs are investigated, and proposed solutions are discussed. A comprehensive search of publications in MEDLINE/PubMed and of commercial product data of IVRs was performed, and the materials, designs, performance, and applications (e.g., contraception, endometriosis, estrogen deficiency and urogenital atrophy) of hormonal IVRs were thoroughly evaluated. Most hormonal IVRs administer female sex hormones, i.e., estrogen and progestogens. In terms of material, IVRs are divided into 3 main groups: silicone, polyurethane, and polyethylene-co-vinyl acetate IVRs. As regards their design, there are 4 major designs for IVRs which strongly affect their performance and the timing and rate of hormone release. Important challenges include reducing the burst release and maintaining the bioavailability of hormones at their site of action over a prolonged period of administration as well as lowering production costs. Hormonal IVRs are a promising method which could be used to facilitate combination therapies by administering multiple drugs in a single IVR while eliminating the side effects of conventional drug administration methods. IVRs could considerably improve womenʼs quality of life all over the world within a short period of time.Keywords
This publication has 166 references indexed in Scilit:
- Management of symptomatic vulvovaginal atrophyMenopause, 2013
- A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of actionEuropean Journal of Pharmaceutical Sciences, 2013
- An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in MacaquesScience Translational Medicine, 2012
- Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in TissueJournal of Virology, 2012
- An Antiretroviral/Zinc Combination Gel Provides 24 Hours of Complete Protection against Vaginal SHIV Infection in MacaquesPLOS ONE, 2011
- Sustained release of proteins from a modified vaginal ring deviceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Local Effects of Vaginally Administered Estrogen TherapyJournal of Pelvic Medicine and Surgery, 2009
- Intravaginal oestrogen and progestin administration: advantages and disadvantagesBest Practice & Research Clinical Obstetrics & Gynaecology, 2008
- Release of 17-Beta-Oestradiol from a Vaginal Ring in Postmenopausal Women: Pharmacokinetic EvaluationGynecologic and Obstetric Investigation, 1994
- Biostability of medical elastomers: a reviewBiomaterials, 1984